RS57882B1 - Formulacija atazanavira i kobicistata za lečenje hiv-a - Google Patents

Formulacija atazanavira i kobicistata za lečenje hiv-a

Info

Publication number
RS57882B1
RS57882B1 RS20181143A RSP20181143A RS57882B1 RS 57882 B1 RS57882 B1 RS 57882B1 RS 20181143 A RS20181143 A RS 20181143A RS P20181143 A RSP20181143 A RS P20181143A RS 57882 B1 RS57882 B1 RS 57882B1
Authority
RS
Serbia
Prior art keywords
cobicistat
atazanavir
treatment formulation
hiv treatment
hiv
Prior art date
Application number
RS20181143A
Other languages
English (en)
Inventor
Otilia May Yue Koo
Faranak Nikfar
Jing Tao
Niranjan Kumar Kottala
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57882(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of RS57882B1 publication Critical patent/RS57882B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20181143A 2013-10-07 2014-10-06 Formulacija atazanavira i kobicistata za lečenje hiv-a RS57882B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07
EP14786421.9A EP3054926B1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat
PCT/US2014/059310 WO2015054133A1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat

Publications (1)

Publication Number Publication Date
RS57882B1 true RS57882B1 (sr) 2019-01-31

Family

ID=51743576

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20181143A RS57882B1 (sr) 2013-10-07 2014-10-06 Formulacija atazanavira i kobicistata za lečenje hiv-a
RS20220859A RS63570B1 (sr) 2013-10-07 2014-10-06 Formulacija atazanavira i kobicistata za lečenje hiv-a

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20220859A RS63570B1 (sr) 2013-10-07 2014-10-06 Formulacija atazanavira i kobicistata za lečenje hiv-a

Country Status (27)

Country Link
US (2) US20160038502A1 (sr)
EP (2) EP3054926B1 (sr)
JP (2) JP6574415B2 (sr)
KR (1) KR102286386B1 (sr)
CN (1) CN106029058A (sr)
AU (1) AU2014332200B2 (sr)
BR (1) BR112016007526A8 (sr)
CA (1) CA2926650A1 (sr)
CL (1) CL2016000787A1 (sr)
CY (1) CY1121105T1 (sr)
DK (2) DK3421033T3 (sr)
EA (1) EA031172B1 (sr)
ES (2) ES2693580T3 (sr)
HR (2) HRP20221126T1 (sr)
HU (1) HUE059757T2 (sr)
IL (1) IL244881B (sr)
LT (2) LT3054926T (sr)
MX (1) MX368268B (sr)
MY (1) MY178960A (sr)
PE (1) PE20160596A1 (sr)
PL (2) PL3054926T3 (sr)
PT (2) PT3421033T (sr)
RS (2) RS57882B1 (sr)
SA (1) SA516370891B1 (sr)
SG (1) SG11201602501VA (sr)
SI (2) SI3421033T1 (sr)
WO (1) WO2015054133A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3496719B1 (en) * 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) * 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
BRPI0717171B1 (pt) * 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT

Also Published As

Publication number Publication date
RS63570B1 (sr) 2022-10-31
LT3421033T (lt) 2022-11-10
CL2016000787A1 (es) 2016-11-25
DK3421033T3 (da) 2022-10-10
DK3054926T3 (en) 2018-10-29
PT3421033T (pt) 2022-09-23
BR112016007526A8 (pt) 2020-03-03
SI3421033T1 (sl) 2022-11-30
EA201690594A1 (ru) 2016-09-30
HRP20181582T1 (hr) 2018-11-30
BR112016007526A2 (pt) 2017-08-01
CN106029058A (zh) 2016-10-12
EA031172B1 (ru) 2018-11-30
KR102286386B1 (ko) 2021-08-05
JP6574415B2 (ja) 2019-09-11
EP3421033A1 (en) 2019-01-02
SA516370891B1 (ar) 2018-08-08
AU2014332200B2 (en) 2018-10-04
MX2016004078A (es) 2016-06-06
HUE059757T2 (hu) 2023-01-28
LT3054926T (lt) 2018-11-12
HRP20221126T1 (hr) 2022-11-25
KR20160060764A (ko) 2016-05-30
CY1121105T1 (el) 2019-12-11
EP3054926B1 (en) 2018-07-25
ES2927484T3 (es) 2022-11-07
PE20160596A1 (es) 2016-06-15
ES2693580T3 (es) 2018-12-12
PL3054926T3 (pl) 2018-12-31
CA2926650A1 (en) 2015-04-16
SI3054926T1 (sl) 2018-10-30
EP3054926A1 (en) 2016-08-17
MY178960A (en) 2020-10-26
EP3421033B1 (en) 2022-07-27
AU2014332200A1 (en) 2016-05-19
US20160038502A1 (en) 2016-02-11
IL244881A0 (en) 2016-05-31
US20190358240A1 (en) 2019-11-28
MX368268B (es) 2019-09-26
SG11201602501VA (en) 2016-04-28
JP2019011334A (ja) 2019-01-24
JP2016532649A (ja) 2016-10-20
WO2015054133A1 (en) 2015-04-16
PL3421033T3 (pl) 2022-10-03
PT3054926T (pt) 2018-10-26
IL244881B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
ZA201601344B (en) Methods and compositions for rna-guided treatment of hiv infection
HK1246296A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途
HK1223615A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HRP20181582T1 (hr) Formulacija atazanavira i kobicistata za liječenje hiv-a
HK1223855A1 (zh) 拉喹莫德和氟吡汀組合物用於治療多發性硬化症
PL3166642T3 (pl) Transdermalne preparaty pergolidu i ich zastosowanie
EP2968127A4 (en) LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION
AU2013101402A4 (en) Timber treatment formulations and methods of use